HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI-powered insights, today announced the launch of the in...
Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount Sinai, in New ...
The companies will collaborate to apply ShapeTX’s AAVid™ capsid discovery platform and transgene engineering technology along with Otsuka&...
IVIS® Spectrum 2 and IVIS SpectrumCT 2imaging systems — new flagship platforms setting the standard in high-throughput performance and versat...
“We took a big step forward in our ongoing commitment to deliver sustainable solutions to our customers, quantifying the impact of our proprietary ap...
STARLIMS, a leading provider of enterprise informatics solutions, announces the expansion of its solution suite through the strategic acquisition of Labste...
Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new chromosomal microarray designed to improve cytogenetic r...
One in Four American Adults Would Rather Not Know They Have Cancer A new study from The Harris Poll, commissioned by Bayer, suggests fear factors ...
Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent ...
Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire Pheno...
Australia's Monash University and American firm Moderna have announced the establishment of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA...
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation. Custo...
Highlights: Reported revenue of $1.67 billion declined 2.7% year-over-year, and decreased 2.3% on a core(1) basis. GAAP net income of $111 millio...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
© 2024 Biopharma Boardroom. All Rights Reserved.
